Atossa Therapeutics Inc.

News & Events

Press Releases

In The Media

1. Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference

   PR Newswire JUN 2, 2025 8:45 AM EDT
   Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference PR Newswir...
   READ ARTICLE

2. Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22

   ACCESS Newswire MAY 20, 2025 9:00 AM EDT
   SEATTLE, WASHINGTON / ACCESS Newswire / May 20, 2025 / Atossa Therapeutics, Inc. (Nasdaq:ATOS)...
   READ ARTICLE

3. Atossa Therapeutics Announces Full Results from I?SPY?2 Endocrine?Optimization Sub?Study Evaluating Low?Dose (Z)?Endoxifen

   PR Newswire MAY 14, 2025 8:15 AM EDT
   Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimizati...
   READ ARTICLE

4. Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update

   PR Newswire MAY 13, 2025 8:00 AM EDT
   Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Updat...
   READ ARTICLE

5. Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio

   GlobeNewswire APR 30, 2025 8:45 AM EDT
   SEATTLE, April 30, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Ato...
   READ ARTICLE

6. Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025

   GlobeNewswire APR 29, 2025 8:45 AM EDT
   SEATTLE, April 29, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Ato...
   READ ARTICLE

7. Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio

   GlobeNewswire APR 22, 2025 8:45 AM EDT
   SEATTLE, April 22, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Ato...
   READ ARTICLE

8. Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer

   PR Newswire APR 10, 2025 8:00 AM EDT
   Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies f...
   READ ARTICLE

9. Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

   GlobeNewswire MAR 25, 2025 8:00 AM EDT
   Ended 2024 with $71.1 million of cash and cash equivalents and no debt Conference Call an...
   READ ARTICLE

10. Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

    GlobeNewswire MAR 20, 2025 9:13 AM EDT
    SEATTLE, March 20, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Ato...
    READ ARTICLE